Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Recipient : Silo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Silo Pharma Starts Key Safety Study for PTSD Drug SPC-15 at Frontage Labs
Details : The agreement aims for a FDA requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
Product Name : SPC-15
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 14, 2025
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Recipient : Silo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : BAN2401 (lecanemab) is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils, being developed for Alzheimer's disease (AD).
Product Name : BAN201
Product Type : Antibody
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : China National Medical Products Administration (NMPA) announced on February 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™).
Product Name : Convidecia
Product Type : Vaccine
Upfront Cash : Inapplicable
February 26, 2021
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable